Keryx Biopharmaceuticals, Inc. (KERX) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts KERX Hot Sheet
Join SI Premium – FREE
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) reported Q4 EPS of ($0.12), $0.02 better than the analyst estimate of ($0.14).
For earnings history and earnings-related data on Keryx Biopharmaceuticals, Inc. (KERX) click here.
For earnings history and earnings-related data on Keryx Biopharmaceuticals, Inc. (KERX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OppFi Inc. (OPFI) Tops Q3 EPS by 2c ; Offers Guidance
- Celestica (CLS) PT Lowered to $435 at Goldman Sachs
- Materialise NV (MTLS) Reports In-Line Q3 EPS; reaffirms outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
